JP2002516103A - インターロイキン２１およびインターロイキン２２ - Google Patents

インターロイキン２１およびインターロイキン２２

Info

Publication number
JP2002516103A
JP2002516103A JP2000551001A JP2000551001A JP2002516103A JP 2002516103 A JP2002516103 A JP 2002516103A JP 2000551001 A JP2000551001 A JP 2000551001A JP 2000551001 A JP2000551001 A JP 2000551001A JP 2002516103 A JP2002516103 A JP 2002516103A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
sequence
polynucleotide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000551001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002516103A5 (enExample
Inventor
スティーブン エム． ルーベン，
レインハード エブナー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of JP2002516103A publication Critical patent/JP2002516103A/ja
Publication of JP2002516103A5 publication Critical patent/JP2002516103A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000551001A 1998-05-29 1999-05-27 インターロイキン２１およびインターロイキン２２ Withdrawn JP2002516103A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8734098P 1998-05-29 1998-05-29
US60/087,340 1998-05-29
US9980598P 1998-09-10 1998-09-10
US60/099,805 1998-09-10
US13196599P 1999-04-30 1999-04-30
US60/131,965 1999-04-30
PCT/US1999/011644 WO1999061617A1 (en) 1998-05-29 1999-05-27 Interleukins-21 and 22

Publications (2)

Publication Number Publication Date
JP2002516103A true JP2002516103A (ja) 2002-06-04
JP2002516103A5 JP2002516103A5 (enExample) 2006-07-20

Family

ID=27375658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000551001A Withdrawn JP2002516103A (ja) 1998-05-29 1999-05-27 インターロイキン２１およびインターロイキン２２

Country Status (6)

Country Link
US (3) US20030003545A1 (enExample)
EP (1) EP1082433A4 (enExample)
JP (1) JP2002516103A (enExample)
AU (1) AU4208799A (enExample)
CA (1) CA2329274A1 (enExample)
WO (1) WO1999061617A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523682A (ja) * 2003-03-21 2006-10-19 ワイス インターロイキン−２１／インターロイキン−２１受容体のアゴニストを用いた免疫学的障害の治療
JP2007506789A (ja) * 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１を用いた自己免疫疾患の治療方法
JP2007516701A (ja) * 2003-11-05 2007-06-28 アンスティテュ ドゥ ルシェルシュ プール ル デヴロップマーン （イ エール デ） ヒトのｈｉｖ感染に対して抵抗性のバイオマーカーおよびその生物学的適用
JP2007533298A (ja) * 2003-10-10 2007-11-22 ノボ　ノルディスク　アクティーゼルスカブ Ｉｌ−２１の誘導体
JP2011184442A (ja) * 2003-10-10 2011-09-22 Novo Nordisk As Ｉｌ−２１の誘導体
JP2015532294A (ja) * 2012-10-03 2015-11-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル インフルエンザ後の細菌重複感染の予防的処置のための方法および薬学的組成物

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) * 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
EP3112468A1 (en) * 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US20040132136A1 (en) * 1998-09-17 2004-07-08 Zymogenetics, Inc. Mammalian Transforming growth factor beta-9
IL141869A0 (en) 1998-09-17 2002-03-10 Zymogenetics Inc Mammalian transforming growth factor beta-9 (ztgfss9)
US7081528B2 (en) * 1998-10-26 2006-07-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding T cell derived inducible factors
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
WO2000042187A1 (en) * 1999-01-11 2000-07-20 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
KR20010089764A (ko) * 1999-01-11 2001-10-08 둘락 노먼 씨. 인터류킨-17과 관련된 포유류의 사이토카인, 이를코딩하는 폴리뉴클레오티드 및 이의 용도
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
JP2016047051A (ja) * 1999-12-23 2016-04-07 ジェネンテック， インコーポレイテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
DK1897944T3 (da) * 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
TWI238191B (en) * 2000-02-08 2005-08-21 Amgen Inc IL-17 like molecules and uses thereof
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
ES2317898T3 (es) 2000-04-18 2009-05-01 Schering Corporation Usos medicinales de agonistas y antogonistas de il-174.
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
EP1326974B1 (en) * 2000-10-13 2006-12-27 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
ATE501730T1 (de) * 2001-01-25 2011-04-15 Zymogenetics Inc Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
US7471042B2 (en) 2001-02-06 2008-12-30 Panasonic Corporation Plasma display panel with an improved electrode
JP2005510451A (ja) * 2001-02-23 2005-04-21 ジェネティクス インスティテュート，エルエルシー 炎症性障害を治療するための組成物及び方法
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
AU2002367534A1 (en) * 2001-11-06 2003-11-03 Eli Lilly And Company Use of il-19, il-22 and il-24 to treat hematopoietic disorders
US7033787B2 (en) 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
CA2481304A1 (en) * 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
SI1501369T1 (sl) 2002-04-26 2015-10-30 Genentech, Inc. Neafinitetno čiščenje proteinov
WO2004003156A2 (en) * 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production
WO2004016774A1 (ja) * 2002-08-13 2004-02-26 Kirin Beer Kabushiki Kaisha 抑制性nk細胞受容体陽性細胞の増幅方法
WO2004032953A1 (en) * 2002-10-11 2004-04-22 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
EP1731163A2 (en) * 2002-10-11 2006-12-13 Novo Nordisk A/S Treatment of allergic conditions by use of IL 21
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
DK1641822T3 (da) 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
EP1692276B1 (en) 2003-11-19 2010-07-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of inducing memory b cell development and terminal differentiation
ATE506433T1 (de) * 2003-12-19 2011-05-15 Novo Nordisk As Prozessierung von peptiden und proteinen
US20060286629A1 (en) 2003-12-19 2006-12-21 Norby Inga S N Processing of Peptides and Proteins
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
AU2006237329B2 (en) 2005-04-18 2012-04-12 Novo Nordisk A/S IL-21 variants
US7675819B2 (en) * 2005-10-17 2010-03-09 The Johns Hopkins University Volumetric passive sonobuoy array of polyvinylidene fluoride (PVDF) wires
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2007071768A1 (en) * 2005-12-23 2007-06-28 Novo Nordisk A/S Purification of proteins using preparative reverse phase chromatography (rpc)
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
EP2109620B1 (en) * 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
DK2120991T3 (da) * 2007-02-12 2014-04-28 Biotempt Bv Behandling af traumatisk blødning med korte oligopeptider
US20080217002A1 (en) * 2007-03-07 2008-09-11 Floyd Randolph Simonds Sand control screen having a micro-perforated filtration layer
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US20090202475A1 (en) * 2007-11-07 2009-08-13 Genentech, Inc. Compositions and methods for treatment of microbial disorders
AU2016259423B2 (en) * 2007-11-07 2018-11-08 Genentech, Inc. Compositions and methods for treatment of microbial disorders
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
CN102348463B (zh) * 2009-01-12 2014-05-07 健能隆医药技术（上海）有限公司 白介素-22在预防和/或治疗多器官功能障碍综合症(mods)中的用途
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CN103182072B (zh) * 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
US11135268B2 (en) * 2015-07-07 2021-10-05 Fred Hutchinson Cancer Research Center Compositions, kits, and methods using interleukin-17C to promote neural growth and/or neural survival
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
KR20190141695A (ko) 2017-04-13 2019-12-24 센티 바이오사이언시스, 인코포레이티드 병용 암 면역요법
CA3116138A1 (en) 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP4106794A4 (en) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242798A (en) * 1983-07-21 1993-09-07 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5256766A (en) * 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
EP0708178A1 (en) * 1994-10-19 1996-04-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy
EP0839196B1 (en) * 1995-07-19 2005-05-11 Genetics Institute, LLC Human ctla-8 and uses of ctla-8-related proteins
US20030054442A1 (en) * 1998-05-15 2003-03-20 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020177188A1 (en) * 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
ES2292242T5 (es) * 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
US20020182673A1 (en) * 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
US20040132136A1 (en) * 1998-09-17 2004-07-08 Zymogenetics, Inc. Mammalian Transforming growth factor beta-9
US20040043397A1 (en) * 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030180255A1 (en) * 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030203451A1 (en) * 2000-08-24 2003-10-30 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030096969A1 (en) * 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2130919A1 (en) * 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523682A (ja) * 2003-03-21 2006-10-19 ワイス インターロイキン−２１／インターロイキン−２１受容体のアゴニストを用いた免疫学的障害の治療
JP2007506789A (ja) * 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１を用いた自己免疫疾患の治療方法
JP2007533298A (ja) * 2003-10-10 2007-11-22 ノボ　ノルディスク　アクティーゼルスカブ Ｉｌ−２１の誘導体
JP2011184442A (ja) * 2003-10-10 2011-09-22 Novo Nordisk As Ｉｌ−２１の誘導体
JP2012067100A (ja) * 2003-10-10 2012-04-05 Novo Nordisk As Ｉｌ−２１の誘導体
US8450459B2 (en) 2003-10-10 2013-05-28 Novo Nordisk A/S IL-21 derivatives and variants
JP2007516701A (ja) * 2003-11-05 2007-06-28 アンスティテュ ドゥ ルシェルシュ プール ル デヴロップマーン （イ エール デ） ヒトのｈｉｖ感染に対して抵抗性のバイオマーカーおよびその生物学的適用
JP2015532294A (ja) * 2012-10-03 2015-11-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル インフルエンザ後の細菌重複感染の予防的処置のための方法および薬学的組成物

Also Published As

Publication number Publication date
US20030092133A1 (en) 2003-05-15
EP1082433A4 (en) 2003-01-02
US20030003545A1 (en) 2003-01-02
CA2329274A1 (en) 1999-12-02
WO1999061617A1 (en) 1999-12-02
US20070207943A1 (en) 2007-09-06
EP1082433A1 (en) 2001-03-14
AU4208799A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
US20070207943A1 (en) Interleukins-21 and 22
JP2002502589A (ja) ４５個のヒト分泌タンパク質
JP2001520039A (ja) ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２
JP2002521055A (ja) ９８個のヒト分泌タンパク質
JP2002508167A (ja) １１０個のヒト分泌タンパク質
JP2002533058A (ja) ９７個のヒト分泌タンパク質
JP2009131263A (ja) ５０個のヒト分泌タンパク質
US7906634B2 (en) HEMCM42 nucleic acids
JP2005218453A (ja) ８７個のヒト分泌タンパク質
JP2002518010A (ja) ９４個のヒト分泌タンパク質
JP2001524814A (ja) ２８種類のヒト分泌タンパク質
EP1093457B1 (en) Cytokine receptor common gamma chain like
JP2002501738A (ja) ６７個のヒト分泌タンパク質
JP2002512521A (ja) ３２個のヒト分泌タンパク質
WO2000042189A1 (en) Interleukin-20
JP2002500035A (ja) ３６個のヒト分泌タンパク質
JP2001514885A (ja) ７０個のヒト分泌タンパク質
JP2002532092A (ja) プロスタサイクリン刺激因子−２
JP2002520050A (ja) ７１個のヒト分泌タンパク質
US6844170B1 (en) Cytokine receptor common gamma chain like
JP2003524366A (ja) ６４個のヒト分泌タンパク質
JP2003525566A (ja) １２５個のヒト分泌タンパク質
JP2002505871A (ja) ３１個のヒト分泌タンパク質
JP2002501077A (ja) Ｍｅｔｈ１およびｍｅｔｈ２のポリヌクレオチドおよびポリペプチド
JP2002514925A (ja) １９個のヒト分泌タンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060525

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081225